Takeda Pharmaceutical Company Limited (LON:0A87)

London flag London · Delayed Price · Currency is GBP · Price in USD
14.42
+0.32 (2.26%)
At close: Nov 25, 2025
7.61%
Market Cap34.53B
Revenue (ttm)22.20B
Net Income (ttm)166.27M
Shares Outn/a
EPS (ttm)0.10
PE Ratio207.69
Forward PEn/a
Dividend0.43 (2.98%)
Ex-Dividend DateSep 30, 2025
Volume374
Average Volume1,088
Open14.42
Previous Close14.10
Day's Range14.42 - 14.42
52-Week Range12.82 - 15.38
Betan/a
RSI53.48
Earnings DateJan 29, 2026

About LON:0A87

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 47,455
Stock Exchange London Stock Exchange
Ticker Symbol 0A87
Full Company Profile

Financial Performance

In 2024, LON:0A87's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.